Bionano Genomics (BNGO) Net Income towards Common Stockholders (2017 - 2026)

Bionano Genomics has disclosed Net Income towards Common Stockholders across 10 years of filings, most recently posting -$7.4 million for Q2 2026.

• In Q2 2026, Net Income towards Common Stockholders fell 8.25% year-over-year to -$7.4 million; the TTM figure through Jun 2026 stood at -$26.7 million (up 47.89% YoY), while the FY2025 annual figure was -$20.9 million, up 76.47% from the prior year.
• Net Income towards Common Stockholders came in at -$7.4 million for Q2 2026 at Bionano Genomics, up from -$8.3 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $3.0 million in Q4 2024 to a low of -$112.6 million in Q3 2023.
• Average Net Income towards Common Stockholders over 5 years is -$27.3 million, with a median of -$30.7 million recorded in 2022.
• Year-over-year, Net Income towards Common Stockholders plunged 253.88% in 2023 and surged 106.81% in 2024.
• Over 5 years, Net Income towards Common Stockholders stood at -$38.7 million in 2022, then retreated by 13.48% to -$43.9 million in 2023, then surged by 106.81% to $3.0 million in 2024, then plunged by 182.32% to -$2.5 million in 2025, then plunged by 201.87% to -$7.4 million in 2026.
• Per Business Quant data, the three most recent Net Income towards Common Stockholders figures were -$7.4 million in Q2 2026, -$8.3 million in Q1 2026, and -$2.5 million in Q4 2025.